Total Payments
$1.7M
2024 Payments
$174,407
Companies
47
Transactions
527
Medicare Patients
5,663
Medicare Billing
$393,954
Payment Breakdown by Category
Consulting$1.0M (60.9%)
Other$545,703 (31.8%)
Research$79,817 (4.7%)
Travel$29,901 (1.7%)
Food & Beverage$15,124 (0.9%)
Education$35.95 (0.0%)
Gifts$33.37 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $1.0M | 212 | 60.9% |
| Current or prospective ownership or investment interest | $471,720 | 1 | 27.5% |
| Unspecified | $79,817 | 23 | 4.7% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $54,633 | 17 | 3.2% |
| Travel and Lodging | $29,901 | 68 | 1.7% |
| Food and Beverage | $15,124 | 195 | 0.9% |
| Compensation for serving as faculty or as a speaker for a non-accredited and noncertified continuing education program | $14,000 | 4 | 0.8% |
| Honoraria | $5,350 | 5 | 0.3% |
| Education | $35.95 | 1 | 0.0% |
| Gift | $33.37 | 1 | 0.0% |
Payments by Type
General
$1.6M
504 transactions
Research
$79,817
23 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Ocular Therapeutix, Inc. | $473,059 | 14 | $0 (2023) |
| Novartis Pharmaceuticals Corporation | $240,507 | 96 | $0 (2023) |
| Astellas Pharma US Inc | $232,853 | 8 | $0 (2024) |
| Allergan, Inc. | $146,165 | 89 | $0 (2021) |
| Novartis Pharma AG | $116,228 | 35 | $0 (2024) |
| Regeneron Pharmaceuticals, Inc. | $81,544 | 40 | $0 (2024) |
| Boehringer Ingelheim International GmbH | $66,181 | 19 | $0 (2024) |
| ABBVIE INC. | $52,984 | 31 | $0 (2024) |
| Biogen, Inc. | $39,424 | 9 | $0 (2023) |
| Regeneron Healthcare Solutions, Inc. | $30,515 | 35 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $174,407 | 32 | Astellas Pharma US Inc ($105,000) |
| 2023 | $269,465 | 81 | Astellas Pharma US Inc ($127,853) |
| 2022 | $559,656 | 74 | Ocular Therapeutix, Inc. ($472,428) |
| 2021 | $116,820 | 50 | Novartis Pharma AG ($43,722) |
| 2020 | $314,940 | 87 | Novartis Pharmaceuticals Corporation ($142,371) |
| 2019 | $124,522 | 89 | Allergan Inc. ($70,210) |
| 2018 | $97,825 | 71 | Novartis Pharmaceuticals Corporation ($32,384) |
| 2017 | $58,367 | 43 | Boehringer Ingelheim Pharma GmbH & Co.KG ($18,377) |
All Payment Transactions
527 individual payment records from CMS Open Payments — Page 1 of 22
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/20/2024 | ABBVIE INC. | OZURDEX (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: EYE CARE | ||||||
| 12/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,650.00 | General |
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,058.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $1,058.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/25/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Consulting Fee | Cash or cash equivalent | $529.00 | General |
| Category: OPHTHALMOLOGY | ||||||
| 10/17/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $6,600.00 | General |
| 10/02/2024 | Samsung Bioepis Co., Ltd. | — | Consulting Fee | Cash or cash equivalent | $1,200.00 | General |
| 09/19/2024 | ABBVIE INC. | — | Food and Beverage | In-kind items and services | $15.74 | General |
| 09/16/2024 | ABBVIE INC. | — | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| 08/05/2024 | Bausch & Lomb Americas Inc. | XIIDRA (Drug), MIEBO | Food and Beverage | In-kind items and services | $161.38 | General |
| Category: Ophthalmology | ||||||
| 07/23/2024 | Novartis Pharma AG | BEOVU (Drug) | Consulting Fee | Cash or cash equivalent | $1,182.50 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/21/2024 | ABBVIE INC. | OZURDEX (Drug) | Food and Beverage | In-kind items and services | $36.26 | General |
| Category: EYE CARE | ||||||
| 05/17/2024 | Regeneron Healthcare Solutions, Inc. | EYLEA HD (Biological) | Food and Beverage | In-kind items and services | $122.40 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/10/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA (Biological) | Consulting Fee | Cash or cash equivalent | $1,933.75 | General |
| Category: OPHTHALMOLOGY | ||||||
| 05/06/2024 | Regeneron Pharmaceuticals, Inc. | EYLEA HD (Biological) | — | In-kind items and services | $441.03 | Research |
| Study: A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA • Category: OPHTHALMOLOGY | ||||||
| 05/01/2024 | ABBVIE INC. | OZURDEX (Drug) | Consulting Fee | Cash or cash equivalent | $1,100.00 | General |
| Category: EYE CARE | ||||||
| 03/19/2024 | Astellas Pharma US Inc | Izervay (Drug) | Consulting Fee | Cash or cash equivalent | $25,200.00 | General |
| Category: Ophthalmology | ||||||
| 03/16/2024 | Astellas Pharma Global Development | Izervay (Drug) | Food and Beverage | In-kind items and services | $61.18 | General |
| Category: Ophthalmology | ||||||
| 03/14/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,550.00 | General |
| 03/10/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $15,200.00 | General |
| 02/20/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $4,500.00 | General |
| 02/20/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $2,250.00 | General |
| 02/01/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 02/01/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $900.00 | General |
| 01/31/2024 | Boehringer Ingelheim International GmbH | — | Consulting Fee | Cash or cash equivalent | $1,800.00 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CRTH258A2301 | Novartis Pharmaceuticals Corporation | $26,203 | 1 |
| Publication support research related | Novartis Pharma AG | $24,331 | 7 |
| CRTH258A2303 | Novartis Pharma AG | $9,675 | 4 |
| OUTCOMES RESEARCH | Novartis Pharmaceuticals Corporation | $7,525 | 1 |
| A RANDOMIZED, DOUBLE MASKED, ACTIVE CONTROLLED PHASE III STUDY OF THE EFFICACY, SAFETY, AND TOLERABILITY OF REPEATED DOSES OF INTRAVITREAL VEGF TRAP IN SUBJECTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION | Regeneron Pharmaceuticals, Inc. | $3,358 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH HEOR RESEARCH | NOVARTIS PHARMACEUTICALS CORPORATION | $2,130 | 4 |
| BRO-MS-95789 LONGITUDINAL ASSESSMENT OF ELLIPSOID ZONE SUBRETINAL HYPERREFLECTIVE MATERIAL & SUB-RPE DISEASE FEATURES IN NEOVASCULAR AMD IN THE OSPREY | NOVARTIS PHARMACEUTICALS CORPORATION | $2,045 | 1 |
| CLR-3726/BRO-MS -98408 THE IMPACT OF FLUID VOLATILITY ON SUBRETINAL HYPERREFLECTIVE MATERIAL AND ELLIPSOID ZONE INTEGRITY IN NAMD IN THE OSPREY STUDY | NOVARTIS PHARMACEUTICALS CORPORATION | $2,045 | 1 |
| PUBLICATION SUPPORT PROVIDED IN CONNECTION WITH BEOVU RESEARCH | Novartis Pharmaceuticals Corporation | $2,045 | 1 |
| A RANDOMIZED, DOUBLE-MASKED, ACTIVE-CONTROLLED PHASE 2/3 STUDY OF THE EFFICACY AND SAFETY OF HIGH-DOSE AFLIBERCEPT IN PATIENTS WITH DIABETIC MACULAR EDEMA | Regeneron Pharmaceuticals, Inc. | $441.03 | 1 |
| EYLEA CLINICAL DEVELOPMENT PROGRAM | Regeneron Pharmaceuticals, Inc. | $19.50 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 1,354 | 2,329 | $852,414 | $88,247 |
| 2022 | 7 | 1,405 | 2,239 | $737,047 | $88,523 |
| 2021 | 12 | 1,619 | 2,778 | $966,663 | $123,103 |
| 2020 | 9 | 1,285 | 2,353 | $810,446 | $94,081 |
Total Patients
5,663
Total Services
9,699
Medicare Billing
$393,954
Procedure Codes
38
All Medicare Procedures & Services
38 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 67028 | Injection of drug into eye | Facility | 2023 | 136 | 404 | $357,885 | $26,893 | 7.5% |
| 92014 | Established patient complete exam of visual system | Facility | 2023 | 347 | 403 | $159,991 | $19,751 | 12.3% |
| 92134 | Imaging of retina | Facility | 2023 | 534 | 1,023 | $174,933 | $16,906 | 9.7% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 197 | 341 | $92,752 | $15,010 | 16.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 75 | 90 | $37,710 | $6,131 | 16.3% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2023 | 15 | 15 | $9,045 | $1,460 | 16.1% |
| 92004 | New patient complete exam of visual system | Facility | 2023 | 25 | 25 | $13,700 | $1,407 | 10.3% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2023 | 13 | 14 | $3,850 | $445.76 | 11.6% |
| 92083 | Exam of visual field with extended testing | Facility | 2023 | 12 | 14 | $2,548 | $244.20 | 9.6% |
| 67028 | Injection of drug into eye | Facility | 2022 | 142 | 372 | $286,452 | $25,758 | 9.0% |
| 92014 | Established patient complete exam of visual system | Facility | 2022 | 347 | 397 | $157,609 | $20,306 | 12.9% |
| 92134 | Imaging of retina | Facility | 2022 | 570 | 1,010 | $156,550 | $17,787 | 11.4% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 202 | 304 | $75,088 | $13,974 | 18.6% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 106 | 116 | $44,196 | $7,765 | 17.6% |
| 99204 | New patient office or other outpatient visit, 45-59 minutes | Facility | 2022 | 24 | 24 | $13,152 | $2,449 | 18.6% |
| 92235 | Exam of retinal blood vessels using a special camera after injection of a dye | Facility | 2022 | 14 | 16 | $4,000 | $484.62 | 12.1% |
| 67028 | Injection of drug into eye | Facility | 2021 | 155 | 468 | $369,642 | $33,370 | 9.0% |
| 99213 | Established patient outpatient visit, total time 20-29 minutes | Facility | 2021 | 273 | 463 | $111,120 | $21,696 | 19.5% |
| 92134 | Diagnostic imaging of retina | Facility | 2021 | 575 | 1,137 | $181,920 | $20,325 | 11.2% |
| 92014 | Eye and medical examination for diagnosis and treatment, established patient, 1 or more visits | Facility | 2021 | 301 | 335 | $132,995 | $16,816 | 12.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 174 | 219 | $81,030 | $16,253 | 20.1% |
| 67228 | Laser destruction of leaking retinal blood vessels, 1 or more sessions | Facility | 2021 | 11 | 16 | $23,184 | $3,769 | 16.3% |
| 66821 | Removal of recurring cataract in lens capsule using laser | Facility | 2021 | 13 | 15 | $17,295 | $3,596 | 20.8% |
| 99204 | New patient outpatient visit, total time 45-59 minutes | Facility | 2021 | 30 | 30 | $16,440 | $3,135 | 19.1% |
| 92004 | Eye and medical examination for diagnosis and treatment, new patient, 1 or more visits | Facility | 2021 | 22 | 22 | $12,056 | $1,419 | 11.8% |
About Dr. Peter Kaiser, MD
Dr. Peter Kaiser, MD is a Ophthalmology healthcare provider based in Cleveland, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/05/2006. The National Provider Identifier (NPI) number assigned to this provider is 1558300590.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Peter Kaiser, MD has received a total of $1.7M in payments from pharmaceutical and medical device companies, with $174,407 received in 2024. These payments were reported across 527 transactions from 47 companies. The most common payment nature is "Consulting Fee" ($1.0M).
As a Medicare-enrolled provider, Kaiser has provided services to 5,663 Medicare beneficiaries, totaling 9,699 services with total Medicare billing of $393,954. Data is available for 4 years (2020–2023), covering 38 distinct procedure/service records.
Ad
Practice Information
- Specialty Ophthalmology
- Location Cleveland, OH
- Active Since 06/05/2006
- Last Updated 02/11/2008
- Taxonomy Code 207W00000X
- Entity Type Individual
- NPI Number 1558300590
Products in Payments
- Izervay (Drug) $228,061
- BEOVU (Drug) $225,601
- EYLEA (Biological) $69,891
- OZURDEX (Drug) $58,110
- BLZ_BEOVU_OPHTHALMOLOGY (Drug) $40,542
- EYLEA HD (Biological) $31,329
- BROLUCIZUMAB (Drug) $30,769
- Jetrea (Drug) $22,491
- RTH258A_BEOVU_OPHTHALMOLOGY (Drug) $19,661
- TAKHZYRO (Biological) $16,065
- Cimerli (Biological) $11,031
- CIRRUS HD-OCT (Device) $9,637
- Susvimo (Drug) $8,042
- VISUDYNE (Drug) $7,944
- Rhopressa (Drug) $6,656
- EYLEA AFLIBERCEPT INJECTION (Biological) $6,607
- RTH258A (Drug) $5,746
- LUMAKRAS (Drug) $3,932
- YUTIQ (Drug) $3,000
- Constellation (Device) $2,853
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Ophthalmology Doctors in Cleveland
Dr. Justis Ehlers, M.d, M.D
Ophthalmology — Payments: $818,485
Ophthalmology $818,485
William Wiley, M.d, M.D
Ophthalmology — Payments: $775,102
Ophthalmology $775,102
Sunil Srivastava, Md, MD
Ophthalmology — Payments: $668,061
Ophthalmology $668,061
Yasha Modi, M.d, M.D
Ophthalmology — Payments: $244,095
Ophthalmology $244,095
Dr. Douglas Rhee, M.d, M.D
Ophthalmology — Payments: $162,043
Ophthalmology $162,043
Faruk Orge, Md, MD
Ophthalmology — Payments: $156,811
Ophthalmology $156,811